Praxis Precision Medicines, Inc. PRAX Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s operating lease right-of-use asset amortization?
- Praxis Precision Medicines, Inc. (PRAX) reported operating lease right-of-use asset amortization of $197K in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Praxis Precision Medicines, Inc.'s operating lease right-of-use asset amortization decreased by 20.9% year-over-year, from $249K to $197K.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s operating lease right-of-use asset amortization has grown at a -7.4% compound annual growth rate (CAGR), from $1.41M to $1.04M.